DALLAS, April 09, 2019 (GLOBE NEWSWIRE) -- via
OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts,
Inc.) (KALY) (“KALYâ€) today announced an
online presentation scheduled next week for Wednesday, April
17th, where management will provide details on its
patented cannabis extract treatments targeting a $170 million
pharmaceutical market opportunity currently under development. The
company has recently announced ongoing cannabis extract research
and development targeting four specific health issues: Chronic
Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain
Management, and Epilepsy. The market for Type 2 Diabetes is
expected to be a $64 billion market by
2026. The market for COPD treatment is anticipated to
reach $14 billion by
2025. The overall pain management treatment market is
anticipated to reach $83 billion by
2024. The market for epilepsy treatment is anticipated to
reach $9 billion by
2022.
Beyond the four specific cannabis therapies
currently in various stages of research and development, KALY has a
number of additional target therapies in its research pipeline
which will be highlighted in the April
17th presentation.
Between now and the April 17th presentation, KALY plans
to mention several key updates regarding their business operations
separate from the cannabis extract pharmaceutical research and
development business. These announcements will be further
incorporated into the upcoming April 17th
presentation. The announcements and supplementary
presentation material pertains to where KALY is generating revenue
from its patented cannabis extraction process delivering
proprietary extracts for infusion into non-pharmaceutical
commercial products. For instance, KALY recently announced
finalizing its all new 25 mg CBD Extract formulation for beverage
infusion. KALY’s patented extraction process already produces
a 10 mg CBD formulation for Puration, Inc.’s (PURA) (“PURAâ€) leading EVERx CBD Sports
Water. Management plans to include in the presentation
updates on how the 25 mg CBD Extract formulation pertains to KALY
and PURA’s contract to produce a private labeled CBD water for
Generex Biotechnology, Corp. (GNBT).
KALY is a health and wellness company set to generate revenue from
its patented cannabis extraction technology through overlapping
go-to-market strategies. In addition to developing
pharmaceutical products internally and through partnerships, KALY
is utilizing is patented cannabis extraction process to develop
numerous wellness products both internally and through
partnerships. The first revenue generating contracts signed in
December of 2018 will be reflected in the company’s upcoming annual
report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459